|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the EYE 10-K filed Mar 1, 2007. Net gain on legal contingencies.
We recognized a net gain on legal contingencies of $96.9 million in
2006, primarily from settlement of pending patent litigation, net of costs
incurred. On July 7, 2006, we entered into a settlement agreement with Alcon,
Inc., Alcon Laboratories, Inc., and Alcon Manufacturing Ltd. (collectively, Alcon)
regarding all pending patent litigation between us and Alcon. The settlement
required Alcon to pay us a lump-sum payment of $121 million which was received
in July 2006 and was accounted for in the third quarter. The parties agreed to dismiss all pending
patent litigation in Delaware and Texas, agreed not to sue each other regarding
the patents at issue in those cases, and cross-licensed patents covering
existing features of commercially available phacoemulsification products.
|
| |||||||